CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

The information statement and other materials 3M Company (3M) and Solventum Corporation (Solventum) have filed or will file with the SEC (and oral communications that 3M or Solventum may make) contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements include those containing such words as “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “guidance,” “intends,” “may,” “outlook,” “plans,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would,” or other words of similar meaning. All statements that reflect 3M’s or Solventum’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, forecasts relating to discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth and cash flows) and statements regarding 3M’s or Solventum’s strategy for growth, future product development, regulatory clearances and approvals, competitive position and expenditures. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and changes in circumstances that are difficult to predict. Although each of 3M and Solventum believes that the expectations reflected in any forward-looking statements it makes are based on reasonable assumptions, it can give no assurance that these expectations will be attained and it is possible that actual results may differ materially from those indicated by these forward-looking statements due to a variety of risks and uncertainties. Such risks and uncertainties include, but are not limited to:

  • The effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, and other events beyond Solventum’s control.
  • Unexpected events, such as those related to the COVID-19 public health crisis.
  • Operational execution risks.
  • Damage to our reputation or our brands.
  • Risks from acquisitions, strategic alliances, divestitures and other strategic events.
  • Solventum’s business dealings involving third-party partners in various markets.
  • Solventum’s ability to access the capital and credit markets and changes in Solventum’s credit ratings.
  • Exposure to interest rate and currency risks.
  • The highly competitive environment in which Solventum operates and consolidation in the healthcare industry.
  • Reduction in customers’ research budgets or government funding.
  • The timing and market acceptance of Solventum’s new product and service offerings.
  • Ongoing working relationships with certain key healthcare professionals.
  • Changes in reimbursement practices of governments or private payers or other cost containment measures.
  • Solventum’s ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors.
  • Legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, Foreign Corrupt Practices Act and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates.
  • Potential liabilities related to PFAS (as defined in Solventum’s Form 10 information statement).
  • Risks related to the highly regulated environment in which Solventum operates.
  • Risks associated with product liability claims.
  • Climate change and measures to address climate change.
  • Security breaches and other disruptions to information technology infrastructure.
  • Solventum’s failure to obtain, maintain, protect, or effectively enforce its intellectual property rights.
  • Pension and postretirement obligation liabilities.
  • Any events that adversely affect the sale or profitability of one of Solventum’s key products or the revenue delivered from sales to its key customers.
  • Any failure by 3M to perform any of its obligations under the various separation agreements to be entered into in connection with the separation and distribution.
  • The expected benefits and timing of the separation and the risk that conditions to the separation will not be satisfied and/or that the separation will not be completed within the expected time frame, on the expected terms or at all.
  • A determination by the IRS or other tax authorities that the distribution or certain related transactions should be treated as taxable transactions.
  • The possibility that any consents or approvals required in connection with the separation will not be received or obtained within the expected time frame, on the expected terms or at all.
  • Expected financing transactions undertaken in connection with the separation and risks associated with additional indebtedness.
  • The risk that incremental costs of operating on a standalone basis (including the loss of synergies), costs of restructuring transactions and other costs incurred in connection with the separation will exceed Solventum’s estimates.
  • The impact of the separation on its businesses and the risk that the separation may be more difficult, time-consuming or costly than expected, including the impact on its resources, systems, procedures and controls, diversion of management’s attention and the impact on relationships with customers, suppliers, employees and other business counterparties.

There can be no assurance that the separation, distribution or any other transaction described in the information statement will in fact be consummated in the manner described or at all. The above list of factors is not exhaustive or necessarily in order of importance. For additional information on identifying factors that may cause actual results to vary materially from those stated in forward-looking statements, see the discussions under “Risk Factors” in Solventum’s Form 10 registration statement. Any forward-looking statement speaks only as of the date on which it is made, and each of 3M and Solventum assumes no obligation to update or revise such statement, whether as a result of new information, future events or otherwise, except as required by applicable law.